REG - Hikma Pharmaceutical - Hikma completes acquisition of Teligent

Hikma PharmaceuticalsAnnouncement

03/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220203:nRSC5863Aa&default-theme=true

RNS Number : 5863A  Hikma Pharmaceuticals Plc  03 February 2022

Hikma completes acquisition of Teligent sterile injectable assets

London, 3 February 2022 - Hikma Pharmaceuticals PLC (Hikma), the multinational
pharmaceutical company, today announces that, following its announcement on 17
January that it had agreed to acquire the Canadian assets of Teligent Inc. for
$45.75 million, this transaction has now completed.

The acquisition marks Hikma's expansion into Canada and includes a portfolio
of 25 sterile injectable products, three in-licenced ophthalmic products and a
pipeline of seven additional products, four of which are approved by Health
Canada.

Riad Mishlawi, President of Hikma Injectables, commented, "The completion of
this acquisition expands Hikma's presence in the highly attractive Canadian
injectables market, bringing a strong portfolio of sterile injectable
products, as well as strengthening our pipeline.  We are excited to bring
these important products to our Canadian customers and their patients."

- ENDS -

Enquiries:

Hikma (Investors):

 Susan Ringdal                                                              +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                           +44 (0)20 3892 4389/ +44 (0)7795 896738

 Senior Investor Relations
 Manager
 Layan Kalisse                                                              +44 (0)20 7399 2788/ +44 (0)7970 709912

 Investor Relations Analyst

 

Teneo (Press):
 

 Charles Armitstead          +44 (0)7703 330 269

 North America Media

 Steven Weiss/David Belian

                             +1 732 788 8279/ +1 848 254 4875

 

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and
BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers, and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQTJMFTMTIMMJT